On a global basis, stem cell clinics have proliferated in recent years. This article explores stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
TAMPA, Fla. and CAMBRIDGE, Mass., March 11, 2026 – GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases. [Read more…]
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform
Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease
AUSTIN, Texas, Jan. 29, 2026 –– Gameto, a clinical-stage biotechnology company advancing cell engineering solutions for women’s health, announced that it has exclusively licensed additional intellectual property from Harvard University related to the induction of meiosis in human cells. The IP builds upon prior work conducted under Gameto’s sponsored research agreement with George Church’s laboratory at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering.
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing
Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the market ahead of its planned commercial launch later this year.
Archimedes® One was developed to address a central challenge in cell therapy manufacturing: how to scale adherent cell processes without compromising biology or introducing unnecessary complexity. [Read more…]
Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 17, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the safety of allogeneic mesenchymal stem cell therapies across a broad range of human clinical indications.
The study, titled “Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety Evidence,” reviewed more than 15 years of published human clinical research across more than 60 stem cell studies, approximately 4,000 patients, and multiple disease categories, including cardiovascular, pulmonary, autoimmune, gastrointestinal, renal, and orthopedic conditions. [Read more…]
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 337
- Next Page »